{
  "id": 507228,
  "title": "Traditional prostate cancer risk factors do not predict hormone therapy benefit, study finds",
  "url": "https://urgent.news/2026/08/10/traditional-prostate-cancer-risk-factors-do-not-predict-hormone",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-10T21:20:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-traditional-prostate-cancer-factors-hormone.html"
  },
  "original_language": "en",
  "account": "A groundbreaking study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has revealed that traditional prostate cancer risk factors, such as high-grade disease and cancer extending beyond the prostate, do not predict who will benefit from hormone therapy following surgery. Published in European Urology, the findings emphasize the need for more precise molecular biomarkers to personalize treatment and improve outcomes. After prostate cancer surgery, some patients receive radiation therapy, and doctors may add hormone therapy, which reduces hormone levels that fuel prostate cancer growth. However, hormone therapy can cause side effects. Identifying patients likely to benefit from hormone therapy is crucial to avoid unnecessary side effects. The study analyzed data from five phase 3 randomized clinical trials involving 4,781 patients who underwent prostate cancer surgery and later received radiation therapy. Researchers developed a score based on four high-risk pathological features, but found that the number of these features did not predict whether a patient would benefit more from adding hormone therapy to radiation therapy. Patients with multiple high-risk features still did not experience greater improvement in overall survival or metastasis-free survival from adding hormone therapy compared to those with fewer risk factors. The study's lead author, Dr. Amar Kishan, emphasizes the distinction between predicting risk and predicting treatment benefit, stating that while pathology helps identify aggressive cancers, biomarkers are needed to determine which patients will benefit most from specific therapies.",
  "summary": "A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}